Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDARA Takes Effect With Under-The-Radar Presidential Signature

Executive Summary

Key FDA legislation moves to implementation phase with presidential signature but little fanfare.

You may also be interested in...



On to PDUFA VII? Yes And No, Woodcock Says, With Sentiment Of Fatigue

The CDER director said the US agency is always thinking about the next iteration of the prescription drug user fee program, but added that it has not yet discussed specifics. 

Right-To-Try Opponents Brace For Last Chance To Stop Bill

US House passage sends legislation back to Senate, where it may not garner widespread support.

US FDA Officials Provide Primer On 'Real-World' Data

In a journal article, Center for Drug Evaluation and Research Director Janet Woodcock and colleagues describe the sources of real-word evidence and study designs that can be used to generate such evidence.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS121356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel